<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692002</url>
  </required_header>
  <id_info>
    <org_study_id>CRO2020 - Imperial College Lon</org_study_id>
    <nct_id>NCT01692002</nct_id>
  </id_info>
  <brief_title>Oral Propionate to Treat and Prevent Diabetes</brief_title>
  <official_title>Development of Orally Administered Sodium Propionate to Treat and Prevent Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of these studies is to firstly determine the pharmacokinetic profile of orally
      administered enteric coated sodium propionate. Subsequently, the most efficacious dose at
      improving glucose tolerance following an oral glucose challenge will be determined. The
      investigators will then determine the mechanism of action of propionate, whether it acts by
      altering beta cell function directly or by augmenting the incretin effect or both
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NHS spends £1M per hour, 10% of its yearly budget, treating diabetes. In the UK cases of
      diabetes are expected to top 4 million by 2025. There is an urgent need for new therapies.
      The short chain fatty acid propionate is a natural substance produced by digestion of
      fermentable carbohydrates. Preclinical and early human data demonstrate it improves
      pancreatic function and glucose control. The investigators aim to conduct proof of principle
      studies to determine if oral delivery of propionate improves glucose control in patients at
      risk of developing diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study 1: Peak plasma concentration of propionate</measure>
    <time_frame>at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h</time_frame>
    <description>Dose ranging and pharmacokinetic profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 2: insulinogenic index</measure>
    <time_frame>0-30mins</time_frame>
    <description>oral glucose tolerance dose finding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study 3: Incremental area under the insulin profile</measure>
    <time_frame>0-10mins</time_frame>
    <description>Intravenous glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h</time_frame>
    <description>Plasma insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sodium chloride pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium propionate pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium propionate</intervention_name>
    <description>Sodium propionate capsule or tablet</description>
    <arm_group_label>Sodium propionate pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Placebo capsule or tablet</description>
    <arm_group_label>Sodium chloride pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <arm_group_label>Sodium chloride pill</arm_group_label>
    <arm_group_label>Sodium propionate pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous glucose tolerance test.</intervention_name>
    <arm_group_label>Sodium chloride pill</arm_group_label>
    <arm_group_label>Sodium propionate pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study 1: Healthy men and women aged between 18 and 70 years with BMI between 20-25 kg/m2
        and with normal fasting blood glucose (below5.5mmol/l and HbA1C less than 5.7% will be
        eligible to volunteer.

        Study 2: As for Study 1. Study 3: Cohort 1: Volunteers aged between 30 to 70 with a BMI
        between 25-35 kg/m2 who do not have impaired fasting glucose and have HbA1c below 5.7%.

        Cohort 2: Volunteers aged between 30 to 70 years with a BMI between 25-35 kg/m2 who have
        impaired fasting glucose (between 5.5-7mmol/l) and HbA1C between 5.7% and 6.5%,

          -  Exclusion Criteria:• Type 1 or Type 2 Diabetes

               -  Gained or lost ≥ 3kg weight in the past three months

               -  Taken prescription medicines having an impact on metabolism, appetite regulation,
                  glucose homeostasis and hormonal regulation

               -  Taken any dietary supplements in the last 6 months

               -  Any chronic illness

               -  Cardiovascular disease

               -  Excess alcohol intake

               -  Current smokers

               -  Any gastrointestinal disorder e.g. Crohn's disease, coeliac disease or irritable
                  bowel syndrome

               -  A history of drug or alcohol abuse in the last 2 years

               -  Pregnancy (all women of child bearing age will undergo a pregnancy test).

               -  Pancreatitis

               -  Use of medications likely to interfere with glucose metabolism, appetite
                  regulation, hormonal balance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gavin A Bewick, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John McMichael Centre - Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

